scholarly journals A Pilot Study in Sweden on Efficacy of Benzylpenicillin, Oxytetracycline, and Florfenicol in Treatment of Acute Undifferentiated Respiratory Disease in Calves

Antibiotics ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 736
Author(s):  
Virpi Welling ◽  
Nils Lundeheim ◽  
Björn Bengtsson
Keyword(s):  
Pilot Study ◽  
Respiratory Disease ◽  
Statistical Power ◽  
Response Rates ◽  
Infectious Agents ◽  
First Line ◽  
Treatment Regimens ◽  
Naturally Occurring ◽  
Random Manner ◽  
Acquired Antibiotic Resistance

Bovine respiratory disease (BRD) is a major indication for antibiotic treatment of cattle worldwide and some of the antibiotics used belong to classes of highest priority among those listed by WHO as critically important for human medicine. To preserve the efficacy of “newer” antibiotics, it has been suggested that “older” drugs should be revisited and used when possible. In this pilot study, we evaluated the efficacy of benzylpenicillin (PEN), oxytetracycline (OTC), and florfenicol (FLO) for treatment of naturally occurring BRD on two farms raising calves for slaughter. Farm personnel selected calves for enrolment, assigned calves to one of the three regimens in a systematically random manner, treated the calves, and registered the results. Overall, 117 calves were enrolled in the study. Nineteen calves relapsed in BRD before slaughter and were retreated (16.2%) and three died (2.6%). For PEN, treatment response rates after 30 days, 60 days, and until slaughter were 90.2%, 87.8%, and 80.5%, respectively; for OTC, 90.0%, 85.0%, and 85.0%, respectively; and for FLO, 86.1%, 83.3%, and 77.8%, respectively. There were no statistically significant differences in relapse, mortality, or response rates between the three treatment regimens. This indicates that PEN, OTC, and FLO were equally effective for treatment of BRD but the results need to be confirmed in a more elaborate study with a higher statistical power. The findings support the current recommendations from the Swedish Veterinary Association and the Medical Products Agency to use benzylpenicillin as a first line antibiotic for treatment of calves with undifferentiated respiratory disease in Sweden. Due to differences in the panorama of infectious agents and presence of acquired antibiotic resistance, the findings might not be applicable in other geographical areas.

scholarly journals Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany

2021 ◽  
Vol 10 (5) ◽  
pp. 1061
Author(s):  
Anne-Christin Beatrice Wilde ◽  
Charlotte Lieb ◽  
Elise Leicht ◽  
Lena Maria Greverath ◽  
Lara Marleen Steinhagen ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Response Rates ◽  
Primary Biliary Cholangitis ◽  
Inadequate Response ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Treatment Modification ◽  
Treatment Regimens ◽  
Retrospective Multicenter Study

Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 x upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 x ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 x ULN and bilirubin ≤ 1 x ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67x ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients.

Comparative efficacy of commonly used first-line chemotherapy regimens in advanced pancreatic cancer: A network meta-analysis.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 403-403
Author(s):  
Philip A. Haddad ◽  
Kevin Michael Gallagher ◽  
Dalia Hammoud
Keyword(s):  
Pancreatic Cancer ◽  
English Language ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Response Rates ◽  
The United States ◽  
First Line ◽  
Treatment Regimens ◽  
Inconsistency Analysis

403 Background: Pancreatic adenocarcinoma is one of the deadliest cancers, ranking fourth in mortality and accounting for up to 7% of all cancer related deaths in the United States. For many years, Gemcitabine and its combinations have been the standard first-line treatments for patients with unresectable locally advanced or metastatic pancreatic cancer (aPC). Recently, FOLFIRINOX was shown to be associated with a survival advantage as well. These chemotherapy combinations have not been compared to each other. We conducted this network meta-analysis to evaluate the relative efficacy of the commonly used chemotherapy regimens in patients with aPC. Methods: A review of the medical literature was conducted using online databases. Inclusion criteria consisted of English language; diagnosis of aPC; treatment with Gemcitabine (GEM) combined with Capecitabine (CAPE), Erlotinib (ERLO), or nab-Paclitaxel (NABPAC) and treatments with FOLFIRINOX; and randomized studies reporting survival and response rates. A frequentists network meta-analysis was conducted using netmeta package and random-effects model. Results: Six studies comprising a total of 2,717 participants were included. FOLFIRINOX demonstrated a significantly better relative risk (RR) of progression and death (P&D) followed by GEM+NABPAC, GEM+ERLO, GEM+CAPE, and GEM in a decreasing order. When compared to GEM-based combination as a group, FOLFIRINOX maintained its superior RR for P&D. Moreover, FOLFIRINOX and GEM+NABPAC had significantly better response rates than GEM+CAPE and GEM+ERLO. Inconsistency analysis did not reveal any significant differences between direct and indirect estimates. Conclusions: This network meta-analysis is the first to compare and rank commonly used treatment regimens in aPC. It indicates that FOLFIRINOX combination seems to be superior to GEM-based combinations with respect to P&D as well as response rates. Nevertheless, among GEM-based combinations, GEM+NABPAC seems to have the best profile given its lower RR for P&D and higher response rates.

Stimulation of non-opsonic phagocytosis in avian respiratory phagocytes

1988 ◽  
Vol 46 ◽  
pp. 140-141
Author(s):  
T. Caceci ◽  
T. Toth ◽  
R.H. Pyle ◽  
P.B. Siegel ◽  
D. Ochs
Keyword(s):  
Respiratory Disease ◽  
Respiratory System ◽  
Phagocytic Activity ◽  
Pasteurella Multocida ◽  
Cell Types ◽  
Infectious Agents ◽  
First Line ◽  
Air Sacs ◽  
Disease Costs ◽  
Stimulation Of

Avian respiratory disease costs the U. S. poultry industry millions of dollars per year in lost production. The avian respiratory system, while similar in many ways, differs from that of mammals anatomically, physiologically, and in its response to invasion by infectious agents. One of the least understood components is the variety of cell types collectively referred to as avian respiratory phagocytes (ARP), the first line of defense against invasion. The resident ARP population is normally very low, but numbers increase in response to certain stimuli. We undertook a study to quantify the extent of ARP influx and the degree of increase in phagocytic activity in response to the presence of non-pathogenic Pasteurella multocida. Chickens were stimulated by intratracheal inoculation of P. multocida, and the ARP's collected by lavage of the lungs and air sacs. Control birds were inoculated with vehicle carrying no P. multocida, and then lavaged.

scholarly journals Forms and Methods for Interferon's Encapsulation

2021 ◽  
Author(s):  
Thelvia I. Ramos ◽  
Carlos A Villacis ◽  
Nelson Santiago Vispo ◽  
Leandro Santiago Padilla ◽  
Seidy Pedroso Santana ◽  
...  
Keyword(s):  
Viral Infections ◽  
Biological Activities ◽  
Clinical Results ◽  
Regulatory Agencies ◽  
Infectious Agents ◽  
First Line ◽  
Innate And Adaptive Immunity ◽  
Treatment Regimens ◽  
Considerable Impact ◽  
Natural Cell

Interferons (IFNs) are cytokines involved in the immune response that act on innate and adaptive immunity. These proteins are natural cell-signaling glycoproteins expressed in response to viral infections, tumors, and biological inducers and constitute the first line of defense of vertebrates against infectious agents. They have been marketed for more than 30 years with considerable impact on the global therapeutic protein market thanks to their diversity in terms of biological activities. They have been used as single agents or with combination treatment regimens, demonstrating promising clinical results, resulting in 22 different formulations approved by regulatory agencies. The 163 clinical trials with currently active IFNs reinforce their importance as therapeutics for human health. However, their application has presented difficulties due to the molecules&rsquo; size, sensitivity to degradation, and rapid elimination from the bloodstream. For some years now, work has been underway to obtain new drug delivery systems to provide adequate therapeutic concentrations for these cytokines, decrease their toxicity and prolong their half-life in the circulation. Although different research groups have presented various formulations that encapsulate IFNs, to date, there is no formulation approved for use in humans. The current review exhibits an updated summary of all encapsulation forms presented in the scientific literature for these cytokines IFN&alpha;, IFN&szlig;, and IFN&gamma;, from the year 1996 to the year 2021, considering parameters such as: encapsulating matrix, route of administration, and encapsulation.

Pathology of Bone Cells in Pigs with Experimental Turbinate Osteoporosis (Atrophic Rhinitis)

1971 ◽  
Vol 29 ◽  
pp. 304-305
Author(s):  
A. W. Fetter ◽  
C. C. Capen
Keyword(s):  
Mucous Membrane ◽  
Bone Cells ◽  
Atrophic Rhinitis ◽  
Infectious Agents ◽  
Metabolic Disturbances ◽  
Progressive Reduction ◽  
Naturally Occurring ◽  
Fundamental Cause ◽  
Osteocytic Osteolysis ◽  
Uncertain Etiology

Atrophic rhinitis in swine is a disease of uncertain etiology in which infectious agents, hereditary predisposition, and metabolic disturbances have been reported to be of primary etiologic importance. It shares many similarities, both clinically and pathologically, with ozena in man. The disease is characterized by deformity and reduction in volume of the nasal turbinates. The fundamental cause for the localized lesion of bone in the nasal turbinates has not been established. Reduced osteogenesis, increased resorption related to inflammation of the nasal mucous membrane, and excessive resorption due to osteocytic osteolysis stimulated by hyperparathyroidism have been suggested as possible pathogenetic mechanisms.The objectives of this investigation were to evaluate ultrastructurally bone cells in the nasal turbinates of pigs with experimentally induced atrophic rhinitis, and to compare these findings to those in control pigs of the same age and pigs with the naturally occurring disease, in order to define the fundamental lesion responsible for the progressive reduction in volume of the osseous core.

scholarly journals Botulinum Toxin: An Update on Pharmacology and Newer Products in Development

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 58
Author(s):  
Supriyo Choudhury ◽  
Mark R. Baker ◽  
Suparna Chatterjee ◽  
Hrishikesh Kumar
Keyword(s):  
Botulinum Toxin ◽  
Clinical Use ◽  
First Line ◽  
High Demand ◽  
Short Term ◽  
Medical Specialties ◽  
Naturally Occurring ◽  
Pharmacokinetic Properties ◽  
Clinical Benefits ◽  
First Line Treatment

Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects. To cater for the high demand across various medical specialties, at least six US Food and Drug Administration (FDA)-approved formulations of BoNT are currently available for diverse labelled indications. The toxo-pharmacological properties of these formulations are not uniform and thus should not be used interchangeably. Synthetic BoNTs and BoNTs from non-clostridial sources are not far from clinical use. Moreover, the study of mutations in naturally occurring toxins has led to modulation in the toxo-pharmacokinetic properties of BoNTs, including the duration and potency. We present an overview of the toxo-pharmacology of conventional and novel BoNT preparations, including those awaiting imminent translation from the laboratory to the clinic.

scholarly journals Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3142
Author(s):  
Alissa Groenendijk ◽  
Filippo Spreafico ◽  
Ronald R. de Krijger ◽  
Jarno Drost ◽  
Jesper Brok ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Tumor Recurrence ◽  
Wilms Tumor ◽  
Clinicopathological Characteristics ◽  
Copy Number Variations ◽  
First Line ◽  
Prognostic Variables ◽  
Treatment Regimens ◽  
International Collaborations ◽  
Patients Experience

In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

scholarly journals Physical activity in the classroom to prevent childhood obesity: a pilot study in Santiago, Chile

2017 ◽  
Vol 6 ◽  
Author(s):  
Francisco Mardones ◽  
Pilar Arnaiz ◽  
Johana Soto-Sánchez ◽  
Juana Saavedra ◽  
Angélica Domínguez ◽  
...  
Keyword(s):  
Physical Activity ◽  
Blood Pressure ◽  
Pilot Study ◽  
Grip Strength ◽  
Statistical Power ◽  
Physical Activity Intervention ◽  
Hand Grip Strength ◽  
Control Group ◽  
High Waist Circumference ◽  
Hand Grip

AbstractThis paper describes a 4-month pilot study that tested the suitability of a physical activity intervention for first graders (children aged 6 and 7 years) in a public school in Santiago, Chile. Teachers were trained to deliver the programme in the classroom during the school day. Teachers were surveyed to determine if this intervention fit within their curriculum and classroom routines and they reported in a focus group that it was suitable for them. All children actively participated in the programme and positive changes in their attitudes towards physical activity were observed by their teachers. Anthropometrics, blood pressure and hand grip strength were measured in the students. A significant reduction was observed in children with high waist circumference ≥ 90th percentile, and in mean systolic blood pressure. However, statistical power values for those comparisons were rather low. Anthropometry and hand grip strength were not modified. The latter calculations and the lack of a control group are showing the weaknesses of this pilot study and that further research with a larger sample size and an experimental design is strongly needed.

Sign in / Sign up

Export Citation Format

Share Document